Nominal conc. of GBT (μg/mL) | S9 mix | Time hours a) | Mean total aberrant metaphases | Mean total aberrations | Mean of PP+ER | Relative cell counts (%) |
---|---|---|---|---|---|---|
6 h treatment (+S9) | ||||||
0 | + | 6-18 | 0.5/0.5 | 1.0/1.0 | 3.0 + 0.0 | 100 |
1250 | + | 6-18 | 1.0/1.0 | 2.0/2.0 | 0.5 + 0.0 | 96 |
2500 | + | 6-18 | 1.5/1.0 | 2.0/1.5 | 1.0 + 0.0 | 96 |
5000 | + | 6-18 | 2.0/1.5 | 2.5/2.0 | 2.0 + 0.0 | 85 |
CPA 6 | + | 6-18 | 30.0/29.5** | 44.0/43.5 | 1.0 + 0.0 | 62 |
6 h treatment (-S9) | ||||||
0 | - | 6-18 | 0.0/0.0 | 0.0/0.0 | 1.0 + 0.0 | 100 |
1250 | - | 6-18 | 0.0/0.0 | 0.0/0.0 | 1.0 + 0.0 | 94 |
2500 | - | 6-18 | 2.5/2.5 | 2.5/2.5 | 1.0 + 0.0 | 92 |
5000 | - | 6-18 | 0.5/0.5 | 1.0/1.0 | 2.0 + 0.0 | 83 |
EMS 800 | - | 6-18 | 22.5/22.0** | 34.0/33.0 | 0.5 + 0.0 | 63 |
22 h treatment (-S9) | ||||||
0 | - | 22-2 | 0.0/0.0 | 0.0/0.0 | 1.0 + 0.0 | 100 |
1250 | - | 22-2 | 0.0/0.0 | 0.0/0.0 | 1.5 + 0.0 | 94 |
2500 | - | 22-2 | 0.5/0.5 | 1.0/1.0 | 0.5 + 0.0 | 89 |
5000 | - | 22-2 | 2.0/1.5 | 3.5/3.0 | 1.0 + 0.0 | 80 |
EMS 600 | - | 22-2 | 31.5/31.5** | 46.0/46.0 | 1.0 + 0.0 | 54 |